No idea on entry point lol. personally, i think now is a great...

No idea on entry point lol. personally, i think now is a great entry point, but obviously at low prices big percentages happen quickly so who knows.

My guess would be next CR will be small again. similar amount, but unless you know a CR has to happen that quarter, the amount share prices move probably make it irrelevant to worry about the effect of a CR 6-9 months away.

The thing i'm not sure about is the Nanocelle platform. they're going through patent procedures still and as far as i'm aware that should finish soon. Sean's always talked about licencing agreements, but i'm guessing nothing much can be done until they have it patented. that's a pretty underrated catalyst i think.

Revenue-wise, it is quite possible for a lot of things to fall into place very quickly and kind of unexpectedly. Between the UK agreement, US agreement, SAS sales increasing (especially once the observational study starts). Australian nutraceuticals growing (note: their are a lot of people on instagram recieving medlab products which they wouldn't pay for and so would add to inventory or marketing costs where the only return is 'brand building') and possible licencing agreements for nanocelle. while everything is small at the moment, it could suddenly all increase at the same time, which is what i think would cause speculation with the free bet on nanabis registration in 2-3 years.

On the other hand, maybe none of it comes together and costs blow out for little revenue gain and the only thing worth buying for is a bet on nanabis success.